Zhejiang Ausun Pharmaceutical Co Ltd. Stock Analysis 603229.SS

Zhejiang Ausun Pharmaceutical Co., Ltd. engages in the manufacture, sale, research and development of pharmaceutical intermediates and raw materials. The company is headquartered in Taizhou, Zhejiang and currently employs 1,328 full-time employees. The company went IPO on 2017-05-09. The firm also provides custom manufacturing, R&D services, and other services to customers. The specialty API and intermediates business provides global generic drug manufacturers with services including non-patent infringement process design, process development and research, pharmaceutical regulatory filing, and cGMP standard commercial production for drugs with expired or soon-to-expire patents. CRO/CDMO/CMO business provides domestic and foreign pharmaceutical companies with new drug process development and product preparation from preclinical, clinical, to commercialization stages. The formulation business develops specialty formulations. The innovative drug business includes investing in new drug companies, and introducing and developing new drugs.